posted on 2016-09-01, 00:00authored byYudao Shen, Magdalena M. Szewczyk, Mohammad
S. Eram, David Smil, H. Ümit Kaniskan, Renato Ferreira de Freitas, Guillermo Senisterra, Fengling Li, Matthieu Schapira, Peter
J. Brown, Cheryl H. Arrowsmith, Dalia Barsyte-Lovejoy, Jing Liu, Masoud Vedadi, Jian Jin
Well-characterized
selective inhibitors of protein arginine methyltransferases
(PRMTs) are invaluable chemical tools for testing biological and therapeutic
hypotheses. Based on 4, a fragment-like inhibitor of
type I PRMTs, we conducted structure–activity relationship
(SAR) studies and explored three regions of this scaffold. The studies
led to the discovery of a potent, selective, and cell-active dual
inhibitor of PRMT4 and PRMT6, 17 (MS049). As compared
to 4, 17 displayed much improved potency
for PRMT4 and PRMT6 in both biochemical and cellular assays. It was
selective for PRMT4 and PRMT6 over other PRMTs and a broad range of
other epigenetic modifiers and nonepigenetic targets. We also developed 46 (MS049N), which was inactive in biochemical and cellular
assays, as a negative control for chemical biology studies. Considering
possible overlapping substrate specificity of PRMTs, 17 and 46 are valuable chemical tools for dissecting specific
biological functions and dysregulation of PRMT4 and PRMT6 in health
and disease.